While Yervoy (ipilimumab) is a widely prescribed immune checkpoint inhibitor, certain limitations apply to discounts for this medication. According to a study published in the Journal of Managed Care and Specialty Pharmacy, [1] Medicare beneficiaries who receive Yervoy may be subject to significant out-of-pocket costs due to a lack of discounts at some pharmacies.

Data from DrugPatentWatch.com indicates that Yervoy is protected by several patents that extend its market exclusivity until 2028 at the earliest [2]. This prolonged period of market exclusivity contributes to Yervoy's high prices.

Research by the Kaiser Family Foundation found that, in 2020, a typical 28-day course of Yervoy therapy for a Medicare Advantage plan member cost around $147,000. This expense is a major concern for cancer patients and payers alike [3].

Moreover, studies suggest that limited or no discounts are often available for Yervoy, making it difficult for patients to afford this treatment. This is particularly concerning for individuals with financial constraints or those who do not have access to adequate insurance coverage.

According to the American Cancer Society, there are various programs and resources available to help patients with cancer-related expenses, including Yervoy costs. However, the availability and terms of these programs may vary depending on the patient's circumstances and geographic location.

While some pharmaceutical companies provide patient assistance programs for certain medications, including Yervoy, [4] these programs often have eligibility requirements and limited resources.

In summary, due to its market exclusivity and lack of discount availability, Yervoy can be an expensive treatment option for cancer patients. However, various resources and programs exist to help alleviate some of these costs.

Sources:
[1] Journal of Managed Care and Specialty Pharmacy
[2] DrugPatentWatch.com
[3] Kaiser Family Foundation
[4] American Cancer Society